BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34560013)

  • 1. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
    Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
    Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
    den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
    Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
    Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
    Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
    Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
    Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
    Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
    Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
    Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
    Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of IKZF1 deletions and IKZF1
    Braun M; Pastorczak A; Sędek Ł; Taha J; Madzio J; Jatczak-Pawlik I; Wypyszczak K; Matysiak M; Derwich K; Lejman M; Kazanowska B; Szczepański T; Kowalczyk JR; Mlynarski W;
    Hematol Oncol; 2022 Aug; 40(3):430-441. PubMed ID: 35118711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
    Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
    Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
    Ifversen M; Turkiewicz D; Marquart HV; Winiarski J; Buechner J; Mellgren K; Arvidson J; Rascon J; Körgvee LT; Madsen HO; Abrahamsson J; Lund B; Jonsson OG; Heilmann C; Heyman M; Schmiegelow K; Vettenranta K
    Br J Haematol; 2019 Mar; 184(6):982-993. PubMed ID: 30680711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
    Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
    Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.
    Gupta S; Dai Y; Chen Z; Winestone LE; Teachey DT; Bona K; Aplenc R; Rabin KR; Zweidler-McKay P; Carroll AJ; Heerema NA; Gastier-Foster J; Borowitz MJ; Wood BL; Maloney KW; Mattano LA; Larsen EC; Angiolillo AL; Burke MJ; Salzer WL; Winter SS; Brown PA; Guest EM; Dunsmore KP; Kairalla JA; Winick NJ; Carroll WL; Raetz EA; Hunger SP; Loh ML; Devidas M
    Lancet Haematol; 2023 Feb; 10(2):e129-e141. PubMed ID: 36725118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
    Öfverholm I; Rezayee F; Heyman M; Harila A; Arvidsson L; Schmiegelow K; Norén-Nyström U; Barbany G
    Br J Haematol; 2023 Jul; 202(2):384-392. PubMed ID: 37156607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
    Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
    Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
    Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
    Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.